Using a state-of-the-art imaging platform to test drug sensitivity profiles of pathologic tissues from pediatric patients
The Pharmacotyping Resource, located within the Pharmaceutical Sciences Department, supports the St. Jude value of “Embrace the challenge to create a new tomorrow.” The resource has developed a state-of-the-art imaging platform to test drug sensitivity profiles of a variety of pathologic tissues obtained from children with catastrophic diseases, with a focus on pediatric cancer. Directed by Drs. Jun Yang and Kristine Crews, this resource is supported by a team of researchers with expertise in high-content imaging, drug assay development, preclinical drug evaluation, and research informatics.
Pharmacotyping, i.e., defining inter-patient variability in drug sensitivity, is the essential starting point for correlating drug sensitivity phenotype to patient genomic profiles. Building upon our historical strength in this field, we recently launched an initiative to modernize our pharmacotyping platform to better align with rapid advances in cancer therapy and drug screen technologies.
PerkinElmer Operetta CLS high-content analysis system
The Pharmacotyping Resource leverages new drug screening technology to enable collaborative pharmacogenomics research that will translate into improved cancer treatment outcomes in the future. The integration of tumor cell sensitivity measures with genomic data will drive forward pharmacogenomics discovery research at St. Jude and will guide the development of the next generation of pediatric cancer therapy at St. Jude and beyond.